Description
CAPRELSA
First action · last action
2017-10-19 · 2020-05-22
Transactions
2
First transaction's obligation
$57,808
Base + all options value (sum of deltas)
$38,532
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797P2086D
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2017-10-19+$57,808= $57,808
- Mod P000012020-05-22-$19,276= $38,532
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2017-10-19 | +$57,808 | $57,808 | CAPRELSA |
| Mod P00001· CLOSE OUT | 2020-05-22 | −$19,276 | $38,532 | CAPRELSA |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI X2XMAQLR9DA8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79724A0018 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2024 |
| 36C26124N0260 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $11,882 | FY2024 |
| 36C26023F0186 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $144,553 | FY2023 |
| 36C26223F0045 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $246,001 | FY2023 |
| 36C26223F0022 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $266,652 | FY2023 |
| 36C26222F0606 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $20,049 | FY2022 |
Other recipients under 6505 from 261-NETWORK CONTRACT OFFICE 21 (36C261) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26126P1178 | OPTUM FRONTIER THERAPIES II, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,374 | FY2026 |
| 36C26126P1102 | ENVIGO RMS LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $74,586 | FY2026 |
| 36C26126P0961 | 10X GENOMICS, INC. | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $34,600 | FY2026 |
| 36C26126P0997 | SIERRA RADIOPHARMACY LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $247,204 | FY2026 |
| 36C26126P1008 | OPTUM FRONTIER THERAPIES II, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,374 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26118F0142_3600_V797P2086D_3600 · retrieved 2026-09-26.